Evidence map›Paper›PMID 33463731›Full record

Observational studyJournal of medical virology2021

Follow-up of SARS-CoV-2 positive subgroup from the Asymptomatic novel CORonavirus iNFection study.

Kristin J Meyers, Brian Dillman, Charles Williams, Jianfei Jiang, Nancy Clifford, Jennifer L Miller, Meghan E Jones, Iris A Goetz, Fady T Botros, Jack Knorr and 2 more

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Pooled it
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Kristin J MeyersLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0002-4329-5115
Brian DillmanLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Charles WilliamsLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Jianfei JiangLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Nancy CliffordLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Jennifer L MillerLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Meghan E JonesLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Iris A GoetzLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Fady T BotrosLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Jack KnorrLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
David H MannerLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Brad WoodwardLilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
Eli Lilly (United States) · US

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

A nested longitudinal study within theAsymptomatic novel CORonavirus iNFfection study followed participants with positive nasopharyngeal swab to query for development of symptoms and assess duration of positive reverse transcription-polymerase chain reaction (RT-PCR) test results. Of the 91 participants initially testing positive, 86 participated in follow-up approximately 14 days after study enrollment; of those 86 participants, 19 (22.1%) developed at least one symptom at any time after the initial positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result. The median number of days to symptom development after their initial positive test result was 6 (range 1-29 days). No participants reported a SARS-CoV-2-related hospitalization. The most frequently reported symptoms were fatigue or muscle aches (10.5%), headache (9.3%), fever (5.8%), and shortness of breath (5.8%). Of the 78 participants who submitted a nasopharyngeal swab for repeat RT-PCR testing, 17 (21.8%) remained positive at Day 14, 4 of which continued to test positive at Day 28. These findings reinforce the probable role of silent SARS-CoV-2 infections in community transmission, and that reliance on symptom development will miss a large proportion of infections. Broad testing programs not limited to individuals presenting with symptoms are critical for identifying persons with SARS-CoV-2 infection and ultimately slowing transmission.

Indexed as

AdolescentAdultAgedAged, 80 and overAsymptomatic InfectionsCOVID-19COVID-19 Nucleic Acid TestingCOVID-19 TestingCross-Sectional StudiesDyspneaFatigueFemaleFeverFollow-Up StudiesHeadacheHospitalizationasymptomatic infectionsSARS-CoV-2viral load

Identifiers

PMID33463731
PMCPMC8014630
OpenAlexW3123606601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.